Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Neurodegenerative diseases have had devastating effects on patients' quality of life. These complex diseases have several pathways that are affected to initiate cell death. Current therapies, designed to address only a single target, fall short in mitigating or preventing disease progression, and disease-modifying drugs are desperately needed. Over the past several years, a new paradigm has emerged which has as a goal the targeting of multiple disease etiological pathways. Such "multi-targeted designed drugs" (MTDD) have shown great promise in preclinical studies as neuroprotective agents, as well as being able to afford symptomatic relief to blunt the day-to-day burden of these illnesses. AREAS COVERED: In this review, the authors evaluate the use of chemical scaffolds that led themselves exquisitely to the development of MTDDs in central nervous system disorders. Some of the examples discussed have also transitioned into the clinic, which underscores the importance of pursuing drug discovery programs within the multifunctional arena. EXPERT OPINION: Currently, very little can be done to slow the progress of neurodegeneration. The multifaceted profile of neurodegeneration necessitates a change in paradigm toward the design of compounds that address several drug targets simultaneously. With successful compounds in clinical trials as well as compounds moving into the clinic, support is growing and the feasibility of this approach is now becoming recognized. This review shows that several small molecule scaffolds can be successfully utilized to design MTDD compounds with good CNS pharmacokinetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 1×
“Closer inspection of the activities associated with this neuroprotection indicated that CSC is able to act as a neuroprotective compound through adenosine A2 receptor antagonism [53,54] and MAO-B inhibition: adenosine A1 receptors did not seem to play a role in the neuroprotective activity of caffeinyl-type compounds.”
BackgroundRoth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594 · cited 1×
“While many of these targets are not shared between conditions, many are -- and can serve as primary drug targets both in disease-specific conditions and in approaches that may have utility across several neurodegenerative disorders with demonstrated pathoetiological overlap [9-18].”
BackgroundProtein–RNA interactions: new genomic technologies and perspectives
König, J., Zarnack, K., Luscombe, N. M., & Ule, J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3141 · Cited by 555
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322 · cited 1×
“that the TZDs are neuroprotective in the MPTP and 6-OHdopamine models [67-71].”
BackgroundChoi, J.-S., Braymer, J. J., Nanga, R. P. R., Ramamoorthy, A., & Lim, M. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006091107 · Cited by 264
Small Molecule Modulators of Copper-Induced Aβ Aggregation
Hindo, S. S., Mancino, A. M., Braymer, J. J., Liu, Y., Vivekanandan, S., Ramamoorthy, A., & Lim, M. H. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907045h · Cited by 203 · cited 1×
“reported the development of compounds that were designed to interact with beta-amyloid as well as exhibiting metal-chelating activity [41] (Figure 5).”
Background
Cited by
Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds
Stefanachi, A., Leonetti, F., Pisani, L., Catto, M., & Carotti, A. (2018) · Molecules · doi:10.3390/molecules23020250 · Cited by 673
Hsin, K.-Y., Ghosh, S., & Kitano, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083922 · Cited by 606
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
“[7]; and the other about the molecular networks paradigm from Csermely et al.”
BackgroundRochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
El-Etr, M., Rame, M., Boucher, C., Ghoumari, A. M., Kumar, N., Liere, P., Pianos, A., Schumacher, M., & Sitruk-Ware, R. (2015) · Glia · doi:10.1002/glia.22736 · Cited by 116
Metadata
- Authors
- Geldenhuys, W. J., & Van der Schyf, C. J.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2012-12-12
- Volume
- 8
- Issue
- 2
- Pages
- 115-129
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2144472252
- Cited by
- 57
- References
- 8
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. https://app.cochat.ai/papers/10.1517/17460441.2013.744746
- The paper
- Geldenhuys, W. J., & Van der Schyf, C. J. (2013). Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2013.744746
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.